PubHawk
Annu Rev Pathol January 2017 PMID 27959626

The Pathogenesis of Ebola Virus Disease.

Laura Baseler, Daniel S Chertow, Karl M Johnson, Heinz Feldmann, David M Morens

Full text PDF Download social card

Mentions

9
Peak: 1 in Mar 2018
across 3 sources since Mar 2018

Extended reach

3,460
potential audience

Total likes

17

Video views

689

Mentions per month

Mar 2018 – Nov 2023

Where it's discussed

  • News5 articles
  • X / Twitter2 posts
  • YouTube2 videos

AI synopsis

What people are saying

The discussions highlight varied perspectives on remdesivir's effectiveness, with some referencing historical death rates (e.g., 'Ebola deaths with no treatment were 88%, 60%, & 81%') and analyzing the relative reduction in mortality, which demonstrates a moderate level of analytical engagement and concern over treatment efficacy in the context of the referenced publication.

AgreementModerate agreement

Most discussions tend to support the idea that treatments like remdesivir have measurable impacts on Ebola outcomes and challenge some claims about their efficacy.

InterestModerate interest

Participants show moderate interest, referencing specific statistics and debates about treatment efficacy, indicating they care about the subject's significance.

EngagementModerate engagement

Comments delve into details like death rates and the interpretation of study results, reflecting a reasonable depth of engagement.

ImpactModerate impact

The discussions suggest the article influences perspectives on Ebola treatment, with some expressions implying a shift or reinforcement of opinions about the significance of research findings.

Abstract in brief

  • Ebolaviruses have caused severe hemorrhagic fever outbreaks in Africa for nearly 50 years, with the 2013-2015 West African epidemic being the most significant in terms of scale and impact.
  • This epidemic provided valuable insights into the virus's behavior, symptoms, and potential treatments, highlighting the importance of supportive care for recovery.
  • Future challenges include improving early epidemic control, enhancing patient care in resource-limited areas, and continuing the development and implementation of effective vaccines.
Read the full abstract

Top posts

Most liked on X and Bluesky
Brian Remy
@briancremy · X

Ebola deaths with no treatment (no remdesivir) were 88%, 60% & 81% in the 1976 & 95 epidemics & “has tended to remain at a similarly high level.” (see p. 393). Thus, remdesivir with a death rate of 53.1% means it actually REDUCES Ebola death by ~7-35%. https://t.co/Q97vgYwaPw

Jan 26, 2023 · 2,746 followers View post →
Brian
@BrianRNevada · X

@VigilantFox No- remdesivir is expensive & useless post viral rep., but this is clearly false destroying credibility. https://t.co/XzYb6CIt69 https://t.co/duh9eqySku https://t.co/bah3sOuff4 https://t.co/NCF5Pr4h1I @DrDMartinWorld @drpaulmarik1 @PierreKory @LTCTheresaLong @DocPeteChambers https://t.co/5CPEkzegHW

Nov 19, 2023 · 26 followers View post →

All mentions

Brian
@BrianRNevada · X

@VigilantFox No- remdesivir is expensive & useless post viral rep., but this is clearly false destroying credibility. https://t.co/XzYb6CIt69 https://t.co/duh9eqySku https://t.co/bah3sOuff4 https://t.co/NCF5Pr4h1I @DrDMartinWorld @drpaulmarik1 @PierreKory @LTCTheresaLong @DocPeteChambers https://t.co/5CPEkzegHW

Nov 19, 2023 · 26 followers View post →
Brian Remy
@briancremy · X

Ebola deaths with no treatment (no remdesivir) were 88%, 60% & 81% in the 1976 & 95 epidemics & “has tended to remain at a similarly high level.” (see p. 393). Thus, remdesivir with a death rate of 53.1% means it actually REDUCES Ebola death by ~7-35%. https://t.co/Q97vgYwaPw

Jan 26, 2023 · 2,746 followers View post →